SEOUL-VIOSYS
29.12.2022 15:01:37 CET | Business Wire | Press release
Seoul Viosys (“SVC”) (KOSDAQ: 092190), a global optical semiconductor company, conducted a test on air sterilization by air purifiers sold in the market. The test confirms that bacterial growth and its leakage occur through the filters. The Company announced filters in air purifiers and air sterilizers can cause viral infection and virus spread.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221229005046/en/
[Figure 1] In-house bacterial culture measurement lab (left) in Seoul Viosys, and result of residual bacteria counting within filters (right) (Graphic: Business Wire)
The Company commissioned a research institute K, an internationally certified testing and research institute, to conduct a ‘test on bacterial residue count’ to check how many germs remain within filters. Air purifiers sold in the market were randomly selected and the filter contamination level was checked. For one gram of filter, an average of 70 CFU (colony forming unit) was confirmed, and for yeast and mold, more than 300 CFU per gram. These numbers are three times higher than the bacteria-permissible level, 100 CFU/g, in wet tissues under the current Cosmetics Act of Korea.
In general, air purifier filters need to be replaced, on a regular basis, every 6 months or every year, as the capture performance of filters is compromised due to suspended particles such as captured dust. According to a thesis on the survival period of harmful bacteria in filters (Survival of Microorganisms on HEPA Filters. James T. Walker et al., Applied Biosafety Vol. 16, No. 3, 2011), it has been confirmed that Staphylococcus epidermidis which causes vomiting, stomachache, and diarrhea can live up to five days in filters, and Bacillus atrophaeus can survive for more than 6 days up to 210 days at maximum.
The Bioresearch team of the Company checked bacterial residue inside filters, and then based on the outcome, the team also conducted a ‘virus filtration test (virus passage test).’ After spraying ‘Phi X 174’ virus which is similar to the Covid-19 virus in size and features at a chamber of 60 m3, air purifiers from Company A, B, and C were operated for 10 minutes, respectively. Then, the virus level was measured around the purifier’s outlet area, and virus level was confirmed at 0.005~0.01% compared to the sprayed virus concentration in the air. One virus can multiply up to 1 million to 100 million times at maximum in 5~6 hours, and even if air purifier filter is used, 10,000 viruses, amounting to 0.01%, may not be filtered and may disperse into the air. Usually, as a small number of viruses such as 1,000 flu (influenza) viruses and 10~100 Noroviruses can cause infection, a sterilization system to prevent any micro leakage is required. It has been measured that one droplet of a Covid-19 patient contains 100-1,000 viruses at maximum.
Young Ju Lee, CEO of Seoul Viosys Co., Ltd. said, “Through this test, it has been confirmed that as time goes by, filters can even work as a medium of bacteria growth, and viruses that pass the filter can spread the infection. Filters alone cannot prevent bacterial infection and sterilization will be the best way for disinfection.”
With its dedication to UV LED technology development for the last 20 years, the Company has developed a clean sterilization technology, ‘Violeds.’ As part of the activities to prevent the spread of infection through the air, in 2020, the Company has provided ‘air sterilizers’ for free in 300 SOHO business sites in Korea that combine filters with ‘Violeds’ technology, developed based on the investment of KRW one billion. According to a phone survey on its users in December 2022, 92% of respondents were found to be satisfied, and 83% said they would recommend the product to others, showing that the level of satisfaction with the product is quite high.
About Seoul Viosys
Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “WICOP Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2018). Seoul Viosys has an extensive UV LED portfolio with all wavelengths range (200nm to 1600nm) including ultraviolet rays (UV), visible rays and infrared rays. It holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for strong sterilization and disinfection (UVC), skin regeneration (UVB), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add the advanced VCSEL technology which supports smartphone facial recognition and autonomous driving, and has started its mass production. In January 2020, it introduced a disruptive “WICOP Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/, YouTube, Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221229005046/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 15:13:00 CEST | Press release
QTSP status allows for full control over the digital trust value chain from identity verification to qualified electronic signature (QES) issuance Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity ve
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
